Protein tyrosine kinase receptor inhibitor diagnostic test - Biodesix

Drug Profile

Protein tyrosine kinase receptor inhibitor diagnostic test - Biodesix

Alternative Names: Erlotinib companion diagnostic; Ficlatuzumab companion diagnostic; VeriStrat test

Latest Information Update: 15 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Biodesix
  • Developer AVEO Oncology; Biodesix; European Thoracic Oncology Platform
  • Class Diagnostic agents; Protein diagnostics
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Non-small cell lung cancer
  • No development reported Advanced breast cancer

Most Recent Events

  • 10 Jul 2017 Efficacy data from a retrospective analysis of the phase III LUX-lung 8 trial in Squamous cell carcinoma of the lung released by Biodesix
  • 01 Dec 2015 European Thoracic Oncology Platform completes the EMPHASIS-lung trial in Non-small cell lung cancer (Diagnosis) in United Kingdom, Switzerland, Spain, Netherlands, Israel, Ireland, Italy, Hungary, Greece, Denmark, Belgium, Austria, USA (unspecified route) (NCT01652469)
  • 24 Oct 2014 Veristrat® gets added into the National Comprehensive Cancer Network (NCCN) guidelines for Non-small cell lung cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top